Paul Calabresi Award in Clinical Oncology Research

项目摘要/摘要 保罗·卡拉布雷西临床肿瘤学研究奖(PCACOR)竞争更新的基本原理 申请是继续培养高素质的癌症临床研究人员，称为学者，他们将 成为独立的领导者。这些临床研究负责人将满足持续不断的对受过高度培训的需求 进行关键癌症临床试验和/或关键临床相关研究的院士将为 正在进行从长凳到床边的翻译。通过这一独特的培训计划和我们的专业知识 导师，学者们将成功地学习沟通和协调多学科团队 科学家并将不断增长的科学知识应用于个性化癌症治疗。特定的 目标是：1)为每一位学者设计灵活的个人发展计划，由 来自申请者的多学科咨询委员会，这些申请者可能是受过肿瘤学培训的医学博士、博士临床医生 已完成临床培训或博士水平的基础科学家致力于癌症学术生涯 注重临床；2)通过有意识的方式促进跨学科培训、交流和互动 团队指导和定期以学者为中心的会议，成功创建完成的PCACOR学者 过渡到独立；3)建立一个由训练有素的临床研究领导者组成的多样化队列 将运行新颖、创新的多学科研究议程，以推动我们当前科学的转化 减轻癌症负担。此外，这些训练有素的思想领袖将成为正在进行的 指导循环回到新的实习生。PCACOR的设计融合了我们卓越的能力， 强大的导师，他们将在非常受支持的环境中提供出色的培训和榜样 科罗拉多大学癌症中心的。有经验的项目负责人是Madeleine A.Kane医学博士 和弗吉尼亚·F·博尔赫斯，医学博士，MMSc，都是具有丰富相关经验的教授。量身定做的培训 课程从两年到五年不等，包括学者定制教学精选的核心要求 在课程中，一位学者设计了至少一项癌症临床试验或辅助研究的重大研究项目。 培训期间将重点关注每个学者的具体个人培训需求，以掌握 通过有指导的环境，这些所需的技能将确保过渡到独立。作为一个结果 所有奖学金获得者在第三年前提交NIH或同等资助金。最终的成功是 我们的过往记录证明了这一点。共有22名初级教职员工接受了PCACOR学者培训， 在本供资期间(24项申请中的7项)。18名学者是该校的教员 科罗拉多大学丹佛安舒茨医学院(UCD-AMC)；14人已晋升，均已 多份同行评议的出版物。18个已经从NIH，DOD，ACS获得了同行审查的资金 和/或基于疾病的基础。所有这些公司都设计了至少一项癌症临床试验，其中几项是全国领先的 癌症临床试验。我们的PCACOR成功地产生了翻译癌症临床研究人员 现在和未来。

Project Summary/Abstract The rationale of this Paul Calabresi Award in Clinical Oncology Research (PCACOR) competitive renewal application is to continue to prepare highly qualified cancer clinical researchers, called Scholars, who will become independent leaders. These clinical research leaders will meet the ongoing need for highly trained academicians running pivotal cancer clinical trials and/or the critical clinical correlative studies that will inform ongoing translation from bench to bedside. Through this unique training program and the expertise of our mentors, the Scholars will succeed in learning to communicate and coordinate multidisciplinary teams of scientists and apply the ever growing amount of scientific knowledge to personalize cancer treatment. Specific objectives are to: 1) Design a flexible Individual Development Program for each Scholar selected by the Multidisciplinary Advisory Committee from applicants who may be oncology trained MDs, PhD clinicians with completed clinical training or PhD level basic scientists committed to an academic cancer career with heavy clinical focus; 2) Foster interdisciplinary training, communication and interaction through intentional team mentoring and regular Scholar-centered meetings, creating completed PCACOR Scholars successfully transitioned to independence; 3) Create a diverse cohort of highly trained clinical research leaders that will run novel, innovative multidisciplinary research agendas to move the translational of our current science to reduce the burden of cancer. Also, these highly trained thought leaders will become part of the ongoing mentorship cycle back to new trainees. The PCACOR design incorporates our exceptional faculty as strong mentors who will provide exceptional training and role models in the very richly supported environment of the University of Colorado Cancer Center. Experienced Program Leaders are Madeleine A. Kane, MD, PhD and Virginia F. Borges, MD, MMSc, both Professors with extensive relevant experience. The tailored Training Period lasts from two to five years and includes Core Requirements of a selection of Scholar tailored didactic coursework, a Scholar designed major research project of at least one cancer clinical trial or ancillary study. The Training Period will focus on the specific individual training needs of each Scholar for which mastery of these needed skills through the mentored environment will ensure transition to independence. As an outcomes metric, all Scholars submit an NIH or equivalent grant by the third year. The ultimate success is demonstrated by our track record. A total of twenty-two junior faculty have trained as PCACOR Scholars, seven during the current funding period (out of 24 applications). Eighteen Scholars are faculty members at University of Colorado Denver Anschutz Medical Campus (UCD-AMC); fourteen have been promoted, all have multiple peer-reviewed publications. Eighteen have obtained peer-reviewed funding from NIH, DOD, ACS and/or disease-based foundations. All have designed at least one cancer clinical trial, and several lead national cancer clinical trials. Our PCACOR successfully produces the translational cancer clinical researchers of now and the future.